Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;34(1):121-123.
doi: 10.1016/j.annonc.2022.10.002. Epub 2022 Oct 7.

Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy

Y J Hua  1 , Y L Liu  1 , K Wen  1 , C Kurts  2 , H Wu  3 , Q Mei  4 , J Li  5
Affiliations

Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy

Y J Hua et al. Ann Oncol. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest. Ethics approval and consent to participate This study was approached by the ethic committee of Sun Yat-sen University Cancer Center (B2022-146-01). All participants agreed to take part in the present study. Consent to publish All participants are consent for publication.

References

    1. Jain A., Chia W.K., Toh H.C. Immunotherapy for nasopharyngeal cancer - a review. Chin Clin Oncol. 2016;5:22. - PubMed
    1. Mei Q., Hu G., Yang Y., et al. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study. J Immunother Cancer. 2022;10 - PMC - PubMed
    1. Xia S., Zhang Y., Wang Y., et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51. - PMC - PubMed
    1. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis. 2006;1:23. - PMC - PubMed
    1. Weber R., Fleming V., Hu X., et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310. - PMC - PubMed

Publication types